Vasamed Stock

Vasamed FCF Conversion

The FCF Conversion Rate (FCF/EBITDA) of Vasamed (VSMD) as of Aug 16, 2026 is 85.02 %.

FCF Conversion

85.02 %

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Vasamed is 2026 85.02 % . FCF Conversion Rate (FCF/EBITDA) of Vasamed was 2025 - . It decreases by % lower compared to the previous year.
Access this data via the Eulerpool API

Vasamed Stock analysis

What does Vasamed do? Vasamed Inc is an American company specializing in medical devices and diagnostics. It was founded in 1987 and is headquartered in St. Paul, Minnesota. Vasamed has become a leading manufacturer of devices for non-invasive vascular diagnostics and therapy, as well as for the assessment of vascular function and circulation. Vasamed's business model is based on selling and marketing medical devices and accessories to doctors, hospitals, and medical facilities worldwide. The company aims to provide its customers with innovative, high-quality medical devices and services that help improve patient diagnosis and treatment outcomes. In recent years, Vasamed has continuously expanded its product range. The company operates in various sectors, including the growing treatment options for circulatory and cardiovascular diseases. At the same time, the company also offers products and services to support science and research. In the field of "vascular diagnostics," Vasamed offers devices for determining circulatory disorders, such as laser taxis, ankle-brachial index systems, and laser doppler blood flow measurement devices. These devices are excellent for detecting diseases such as peripheral arterial occlusive disease (PAOD) or diabetes, which are known risk factors for the development of circulatory disorders. In the field of "endothelial function," Vasamed offers devices for measuring vascular health, such as the Endo-PAT system. This system is a non-invasive procedure for measuring the endothelial function of blood vessels, which is important for the prevention of cardiovascular diseases. In the "research and development projects" sector, the company collaborates with academic partners and industry researchers to develop new technologies and diagnostic and therapeutic procedures. Vasamed also participates in clinical trials and scientific conferences to present its research findings and products worldwide. Vasamed has a long history in medical diagnostics and therapy. The company has become one of the leading manufacturers of devices for non-invasive vascular diagnostics and therapy, as well as for the assessment of vascular function and circulation. Taking into account the experience and science that Vasamed has developed, the company aims to support medical professionals in the diagnosis and treatment of patients. Vasamed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vasamed stock

FCF Conversion Rate (FCF/EBITDA) of Vasamed is 85.02 % in 2026.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Vasamed since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Vasamed with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

Cash Flow — Vasamed

All Key Metrics — Vasamed